XERS Projected Dividend Yield
Xeris Biopharma Holdings Inc ( NASDAQ : XERS )Xeris Biopharma Holdings is a pharmaceutical company. Co.'s primary focus is on therapies for patient populations in endocrinology, neurology, and gastroenterology. Co.'s products include: Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes ages two years and older; Keveyis, the U.S. Food and Drug Administration approved therapy for hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev (levoketoconazole), a cortisol synthesis inhibitor used for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. 20 YEAR PERFORMANCE RESULTS |
XERS Dividend History Detail XERS Dividend News XERS Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |